Delivery Order SPE2DB24D3013-SPE2DB25FFPJS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $74,493.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (quantity: 30s) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $74,636.43 for RINVOQ ER 45 mg tablets (28-count units) on August 5, 2025, with completion targeted for August 6, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal vendor, fulfills this delivery...
- The Defense Logistics Agency awarded a $4,008.81 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an August 4, 2025 completion date. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the prime contractor...
- The Defense Logistics Agency awarded a delivery order valued at $3,244.04 to AmerisourceBergen Drug Corp on July 22, 2025, for RINVOQ ER 15 mg tablets (30-count unit dosages), with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract (no set-aside) is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFPJSDelivery Order
The Defense Logistics Agency awarded a $3,173.42 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This non-competitive, non-set-aside contract represents a routine pharmaceutical procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The delivery location is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a typical transaction within AmerisourceBergen's broader role as a critical pharmaceutical supplier to federal military and veteran healthcare systems. The company holds a $999,999,999 IDC with DLA Troop Support Medical through December 2026, which serves as the umbrella contract vehicle enabling routine delivery orders for pharmaceutical products across the Defense Health Agency and other federal healthcare customers. RINVOQ (upadacitinib) is a prescription immunosuppressant medication, and its procurement through the DLA supply chain supports federal healthcare system requirements for treating various inflammatory and autoimmune conditions across military beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/13/25 |